Cargando…

Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities

Rho-class small GTPases are implicated in basic cellular processes at nearly all brain developmental steps, from neurogenesis and migration to axon guidance and synaptic plasticity. GTPases are key signal transducing enzymes that link extracellular cues to the neuronal responses required for the con...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamboni, Valentina, Jones, Rebecca, Umbach, Alessandro, Ammoni, Alessandra, Passafaro, Maria, Hirsch, Emilio, Merlo, Giorgio R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032284/
https://www.ncbi.nlm.nih.gov/pubmed/29925821
http://dx.doi.org/10.3390/ijms19061821
_version_ 1783337478570115072
author Zamboni, Valentina
Jones, Rebecca
Umbach, Alessandro
Ammoni, Alessandra
Passafaro, Maria
Hirsch, Emilio
Merlo, Giorgio R.
author_facet Zamboni, Valentina
Jones, Rebecca
Umbach, Alessandro
Ammoni, Alessandra
Passafaro, Maria
Hirsch, Emilio
Merlo, Giorgio R.
author_sort Zamboni, Valentina
collection PubMed
description Rho-class small GTPases are implicated in basic cellular processes at nearly all brain developmental steps, from neurogenesis and migration to axon guidance and synaptic plasticity. GTPases are key signal transducing enzymes that link extracellular cues to the neuronal responses required for the construction of neuronal networks, as well as for synaptic function and plasticity. Rho GTPases are highly regulated by a complex set of activating (GEFs) and inactivating (GAPs) partners, via protein:protein interactions (PPI). Misregulated RhoA, Rac1/Rac3 and cdc42 activity has been linked with intellectual disability (ID) and other neurodevelopmental conditions that comprise ID. All genetic evidences indicate that in these disorders the RhoA pathway is hyperactive while the Rac1 and cdc42 pathways are consistently hypoactive. Adopting cultured neurons for in vitro testing and specific animal models of ID for in vivo examination, the endophenotypes associated with these conditions are emerging and include altered neuronal networking, unbalanced excitation/inhibition and altered synaptic activity and plasticity. As we approach a clearer definition of these phenotype(s) and the role of hyper- and hypo-active GTPases in the construction of neuronal networks, there is an increasing possibility that selective inhibitors and activators might be designed via PPI, or identified by screening, that counteract the misregulation of small GTPases and result in alleviation of the cognitive condition. Here we review all knowledge in support of this possibility.
format Online
Article
Text
id pubmed-6032284
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60322842018-07-13 Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities Zamboni, Valentina Jones, Rebecca Umbach, Alessandro Ammoni, Alessandra Passafaro, Maria Hirsch, Emilio Merlo, Giorgio R. Int J Mol Sci Review Rho-class small GTPases are implicated in basic cellular processes at nearly all brain developmental steps, from neurogenesis and migration to axon guidance and synaptic plasticity. GTPases are key signal transducing enzymes that link extracellular cues to the neuronal responses required for the construction of neuronal networks, as well as for synaptic function and plasticity. Rho GTPases are highly regulated by a complex set of activating (GEFs) and inactivating (GAPs) partners, via protein:protein interactions (PPI). Misregulated RhoA, Rac1/Rac3 and cdc42 activity has been linked with intellectual disability (ID) and other neurodevelopmental conditions that comprise ID. All genetic evidences indicate that in these disorders the RhoA pathway is hyperactive while the Rac1 and cdc42 pathways are consistently hypoactive. Adopting cultured neurons for in vitro testing and specific animal models of ID for in vivo examination, the endophenotypes associated with these conditions are emerging and include altered neuronal networking, unbalanced excitation/inhibition and altered synaptic activity and plasticity. As we approach a clearer definition of these phenotype(s) and the role of hyper- and hypo-active GTPases in the construction of neuronal networks, there is an increasing possibility that selective inhibitors and activators might be designed via PPI, or identified by screening, that counteract the misregulation of small GTPases and result in alleviation of the cognitive condition. Here we review all knowledge in support of this possibility. MDPI 2018-06-20 /pmc/articles/PMC6032284/ /pubmed/29925821 http://dx.doi.org/10.3390/ijms19061821 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zamboni, Valentina
Jones, Rebecca
Umbach, Alessandro
Ammoni, Alessandra
Passafaro, Maria
Hirsch, Emilio
Merlo, Giorgio R.
Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
title Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
title_full Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
title_fullStr Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
title_full_unstemmed Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
title_short Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
title_sort rho gtpases in intellectual disability: from genetics to therapeutic opportunities
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032284/
https://www.ncbi.nlm.nih.gov/pubmed/29925821
http://dx.doi.org/10.3390/ijms19061821
work_keys_str_mv AT zambonivalentina rhogtpasesinintellectualdisabilityfromgeneticstotherapeuticopportunities
AT jonesrebecca rhogtpasesinintellectualdisabilityfromgeneticstotherapeuticopportunities
AT umbachalessandro rhogtpasesinintellectualdisabilityfromgeneticstotherapeuticopportunities
AT ammonialessandra rhogtpasesinintellectualdisabilityfromgeneticstotherapeuticopportunities
AT passafaromaria rhogtpasesinintellectualdisabilityfromgeneticstotherapeuticopportunities
AT hirschemilio rhogtpasesinintellectualdisabilityfromgeneticstotherapeuticopportunities
AT merlogiorgior rhogtpasesinintellectualdisabilityfromgeneticstotherapeuticopportunities